SEOUL: Drugmaker partners Organon and Samsung Bioepis say they have launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while two other drugmakers entered the market with much more modest discounts to the branded medicine’s list price.
The copycat drug called Hadlima will be listed at US$1,038 (RM4,846) per month, representing an 85% discount of Humira’s current US$6,922 (RM32,315) monthly price, the companies said.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
